NeoGenomics, Inc.
$2.44B- Market cap
- $2.26B
- Debt
- +$341.86M
- Cash
- −$159.62M
Capital structure 87% equity / 13% debt · EV / Revenue 3.35x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NEO stock price at premium vs KMB $17.56 current versus $11.78 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at KMB's multiple
Implied fair value · at NEO's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · KMB FY 2025 (ended Dec 31, 2025).
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 87% equity / 13% debt · EV / Revenue 3.35x
Capital structure 83% equity / 17% debt · EV / Revenue 2.48x · EV / EBITDA 11.27x
KMB carries the larger enterprise value at $40.71B against $2.44B; KMB trades on the lower EV / Revenue multiple (2.48x vs 3.35x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
KIMBERLY-CLARK CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.41x
4.77x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
1.79x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$688.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
Procter & Gamble Company
NEO vs PG
COLGATE PALMOLIVE CO
NEO vs CL
CLOROX CO /DE/
NEO vs CLX
CHURCH & DWIGHT CO INC /DE/
NEO vs CHD
EDGEWELL PERSONAL CARE Co
NEO vs EPC
Johnson & Johnson
NEO vs JNJ
$341.86M
$7.17B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.